<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d97b84fc-7e0b-4f73-804d-522c2448b058"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use CLARITHROMYCIN EXTENDED-RELEASE TABLETS </content>
      <content styleCode="bold">safely and effectively. See full prescribing information for CLARITHROMYCIN EXTENDED-RELEASE TABLETS.</content>
      <content styleCode="bold">
         <br/>
         <br/>
      </content>
      <content styleCode="bold">CLARITHROMYCIN extended-release tablets, for oral use</content>
      <content styleCode="bold">
         <br/>Initial U.S. Approval: 1991</content>
   </title>
   <effectiveTime value="20250410"/>
   <setId root="d5be5f12-6392-4d7d-ab23-ebc205ac1a85"/>
   <versionNumber value="37"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119723554" root="1.3.6.1.4.1.519.1"/>
            <name>Actavis Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5a929920-7f39-4d2c-aaf1-1cd83763d9df"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250410"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0591-2805" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>clarithromycin</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>clarithromycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="H1250JIK0A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CLARITHROMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H1250JIK0A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CLARITHROMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CQ3XH3DET6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="SA1B764746" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="KH7I04HPUU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0591-2805-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140227"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065145" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140227"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">777</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">
               <id root="22aa9784-0896-4b22-9aba-d0d4b5423f9b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Acute Bacterial Exacerbation of Chronic Bronchitis in Adults (<linkHtml href="#LINK_e2d7e4c6-7122-4232-8f33-943f3184b5fd">1.1</linkHtml>)</item>
                           <item>Acute Maxillary Sinusitis (<linkHtml href="#LINK_60aac316-19bd-4ec6-90c2-2cb1f9bf2a08">1.2</linkHtml>)</item>
                           <item>Community-Acquired Pneumonia (<linkHtml href="#LINK_a057b756-72e8-4952-bc6a-91495a584089">1.3</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Clarithromycin extended-release tablets are indicated only for acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, and community-acquired pneumonia in adults. (<linkHtml href="#LINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">1.9</linkHtml>)</paragraph>
                        <paragraph> To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#LINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">1.9</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e2d7e4c6-7122-4232-8f33-943f3184b5fd">
                     <id root="f28c82e2-d0db-4547-82e3-a8663bd1a8e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Acute Bacterial Exacerbation
of Chronic Bronchitis</title>
                     <text>
                        <paragraph>Clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to <content styleCode="italics">Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, </content>or<content styleCode="italics"> Streptococcus pneumoniae [see Indications and Usage (<linkHtml href="#www.splportal.comLINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">1.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_60aac316-19bd-4ec6-90c2-2cb1f9bf2a08">
                     <id root="257f06b2-e3e4-4eaf-b366-363721f94cad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Acute Maxillary Sinusitis</title>
                     <text>
                        <paragraph>Clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to <content styleCode="italics">Haemophilus influenzae, Moraxella catarrhalis, </content>or<content styleCode="italics"> Streptococcus pneumoniae [see Indications and Usage (<linkHtml href="#www.splportal.comLINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">1.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a057b756-72e8-4952-bc6a-91495a584089">
                     <id root="653e11e3-504d-474c-9259-a7effc3ad6e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Community-Acquired
Pneumonia</title>
                     <text>
                        <paragraph>Clarithromycin extended-release tablets are indicated<content styleCode="italics"> [see Indications and Usage (<linkHtml href="#www.splportal.comLINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">1.9</linkHtml>)]</content> for the treatment of mild to moderate infections caused by susceptible isolates due to:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Haemophilus influenzae</content> (in adults)</item>
                           <item>
                              <content styleCode="italics">Haemophilus parainfluenzae</content> (in adults)</item>
                           <item>
                              <content styleCode="italics">Moraxella catarrhalis</content> (in adults)</item>
                           <item>
                              <content styleCode="italics">Mycoplasma pneumoniae, Streptococcus pneumoniae</content>, <content styleCode="italics">Chlamydophila </content>
                              <content styleCode="italics">pneumoniae</content> (in adults)</item>
                        </list>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_78b5c7bb-50b2-4f3d-818b-f20da7c758ce">
                     <id root="9a58c3d2-2ae7-4e51-b7ca-b3682c4d7c1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.9 Limitations of Use</title>
                     <text>
                        <paragraph>Clarithromycin extended-release tablets are indicated only for acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia in adults. The efficacy and safety of clarithromycin extended-release tablets in treating other infections for which clarithromycin immediate-release tablets and clarithromycin granules are approved have not been established.</paragraph>
                        <paragraph> There is resistance to macrolides in certain bacterial infections caused by <content styleCode="italics">Streptococcus pneumoniae</content> and <content styleCode="italics">Staphylococcus aureus</content>. Susceptibility testing should be performed when clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d822dab5-c63c-4e08-8fc4-da88902b0f83">
                     <id root="e31949a9-5218-47d1-9cca-cc4b7588186a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.10 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_94109e27-eafa-4c0d-8722-491533474dd5">
               <id root="84978acc-6445-4ec8-a710-e6c70cbbb1e3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Adults: Clarithromycin extended-release tablets 1 gram every 24 hours for 7 to 14 days (<linkHtml href="#LINK_f54c16f0-71a4-40b5-b438-2103baa3144b">2.2</linkHtml>)</item>
                           <item>Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment (<linkHtml href="#LINK_8d65fe9b-433d-4f67-abce-86e17dc87e62">2.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_1758fcec-7f4f-4b11-af2d-60bafae814e9">
                     <id root="7244c71a-f56d-4736-ac0b-cac84d0c7ef7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration
Instructions</title>
                     <text>
                        <paragraph>Clarithromycin extended-release tablets should be taken with food. Swallow clarithromycin extended-release tablets whole; do not chew, break or crush clarithromycin extended-release tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f54c16f0-71a4-40b5-b438-2103baa3144b">
                     <id root="e9917d73-6a06-4168-9010-0b0792463148"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Adult Dosage</title>
                     <text>
                        <paragraph>The recommended dosages of clarithromycin extended-release tablets for the treatment of mild to moderate infections in adults are listed in Table 1.</paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <caption>Table 1. Adult Dosage Guidelines</caption>
                           <col width="1pt"/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td/>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Clarithromycin Extended-Release Tablets</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Infection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(e</content>
                                       <content styleCode="bold">very 24 hours)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Duration</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(</content>
                                       <content styleCode="bold">d</content>
                                       <content styleCode="bold">ays)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Acute bacterial exacerbation of chronic bronchitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Acute maxillary sinusitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Community-acquired pneumonia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 gram</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8d65fe9b-433d-4f67-abce-86e17dc87e62">
                     <id root="db07cb24-72c5-436c-a852-76d032c78f45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Adjustment
in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>See Table 2 for dosage adjustment in patients with moderate or severe renal impairment with or without concomitant atazanavir or ritonavir-containing regimens <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="0" border="1">
                           <caption>Table 2. Clarithromycin Dosage Adjustments in Patients with Renal Impairment</caption>
                           <col width="1pt"/>
                           <col width="143.15pt"/>
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Recommended </content>
                                       <content styleCode="bold">Clarithromycin</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage Reduction</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with severe renal impairment (CLcr of &lt;30 mL/min)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Reduce the dosage of</paragraph>
                                    <paragraph>Clarithromycin by 50%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with moderate renal impairment (CLcr of 30 to 60 mL/min) taking concomitant atazanavir or ritonavir-containing regimens</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Reduce the dosage of</paragraph>
                                    <paragraph>Clarithromycin by 50%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with severe renal impairment (CLcr of &lt;30 mL/min) taking concomitant atazanavir or ritonavir-containing regimens</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Reduce the dosage of</paragraph>
                                    <paragraph>Clarithromycin by 75%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d54c13cf-42c8-45da-a4a2-e9db5e84fb6b">
                     <id root="9468b177-c84e-46b3-b2a1-7d5ae74e8c65"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Dosage Adjustment
Due to Drug Interactions</title>
                     <text>
                        <paragraph>Decrease the dose of clarithromycin by 50 % when co-administered with atazanavir <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>. Dosage adjustments for other drugs when co-administered with clarithromycin may be recommended due to drug interactions <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">
               <id root="4b104dce-679a-40bd-87d4-651185310fae"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Clarithromycin Extended-release Tablets USP (yellow, film coated, oval shaped, unscored tablets) are available as:</paragraph>
                  <paragraph>•  500 mg: debossed with <renderMultiMedia referencedObject="MM1"/> and “777” on one side.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Extended-release Tablets: 500 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">
               <id root="7704f330-3226-46d0-88a4-a7920af04ae9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text/>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to clarithromycin or any macrolide drug (<linkHtml href="#LINK_ce887b83-48ee-4ca9-9231-eab1a329703e">4.1</linkHtml>)</item>
                           <item>Cisapride and pimozide (<linkHtml href="#LINK_e4f59c92-5998-40cc-8578-7e798f91b9a0">4.2</linkHtml>)</item>
                           <item>History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (<linkHtml href="#LINK_178003bf-593f-4c28-ad3b-acc0dfa94cbf">4.3</linkHtml>)</item>
                           <item>Colchicine in renal or hepatic impairment (<linkHtml href="#LINK_02bb0cce-26c0-4867-aee8-467b7d6f1b4b">4.4</linkHtml>)</item>
                           <item>Lomitapide, lovastatin, and simvastatin (<linkHtml href="#LINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>)</item>
                           <item>Ergot alkaloids (ergotamine or dihydroergotamine) (<linkHtml href="#LINK_9cc1f8ed-10f1-4f31-9b7e-b75811026030">4.6</linkHtml>)</item>
                           <item> Lurasidone (<linkHtml href="#LINK_85c174c5-5b08-4ad3-8048-7377df78b3d7">4.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ce887b83-48ee-4ca9-9231-eab1a329703e">
                     <id root="5dddb2a7-0fb8-495c-9b6a-d0cdfda8464b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_85eabefe-49a6-4e59-9481-e0067c53da5d">5.1</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e4f59c92-5998-40cc-8578-7e798f91b9a0">
                     <id root="0f02bca2-b6ae-4fc9-8c9b-e4a90a5dafa4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Cisapride and
Pimozide</title>
                     <text>
                        <paragraph>Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph> There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_178003bf-593f-4c28-ad3b-acc0dfa94cbf">
                     <id root="7657a04c-f6cc-48f0-9298-d13434ca875a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3 Cholestatic Jaundice/Hepatic
Dysfunction</title>
                     <text>
                        <paragraph>Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_02bb0cce-26c0-4867-aee8-467b7d6f1b4b">
                     <id root="1990bb06-390c-4c98-902e-e572b0de9f5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.4 Colchicine</title>
                     <text>
                        <paragraph>Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">
                     <id root="4f8136a7-4dc5-47a3-a170-798c107e1938"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.5 Lomitapide,
Lovastatin, and Simvastatin</title>
                     <text>
                        <paragraph>Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases <content styleCode="italics">[see Warnings and <content styleCode="italics">Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>) and Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>
                           </content>.</paragraph>
                        <paragraph> Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>) and Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9cc1f8ed-10f1-4f31-9b7e-b75811026030">
                     <id root="5e417987-044b-4de5-a2eb-722ac77d3b9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.6 Ergot Alkaloids</title>
                     <text>
                        <paragraph>Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_85c174c5-5b08-4ad3-8048-7377df78b3d7">
                     <id root="8c5331ae-287c-41d6-a644-523a3199fb4e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.7 Lurasidone</title>
                     <text>
                        <paragraph>Concomitant administration of clarithromycin and lurasidone is contraindicated since it may result in an increase in lurasidone exposure and the potential for serious adverse reactions <content styleCode="italics">[see Drug Interactions (<linkHtml href="#LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_20b62b1d-0b40-4242-93c4-755f63842cae">
                     <id root="62d95daf-7e43-42f8-bed3-3680e88ecabe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.8 Contraindications
for Co-administered Drugs</title>
                     <text>
                        <paragraph>For information about contraindications of other drugs indicated in combination with clarithromycin, refer to their full prescribing information (contraindications section).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5da03a55-6cf3-43ed-aa05-5b795a2fcf91">
               <id root="484b697e-21bd-477c-be03-35eab68359ff"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Severe Acute Hypersensitivity Reactions</content>: Discontinue clarithromycin if occurs (<linkHtml href="#LINK_85eabefe-49a6-4e59-9481-e0067c53da5d">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">QT Prolongation</content>: Avoid clarithromycin in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia (torsades de pointes), hypokalemia/hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics (<linkHtml href="#LINK_86fe4024-e4f4-4584-a1d8-981636e977d4">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Discontinue if signs and symptoms of hepatitis occur (<linkHtml href="#LINK_0de9d9c3-5d44-4afd-9664-d1738d5da0f5">5.3</linkHtml>)</item>
                           <item>Serious adverse reactions can occur due to drug interactions of clarithromycin with colchicine, some lipid-lowering agents, some calcium channel blockers, and other drugs (<linkHtml href="#LINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)</item>
                           <item>Risk of all-cause mortality one year or more after the end of treatment in patients with coronary artery disease. Balance this potential risk with the treatment benefits when prescribing clarithromycin in these patients. (<linkHtml href="#LINK_dcd66ff1-2750-4123-954f-3e51c29a6980">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">
                                 <content styleCode="underline">Clostridium difficile</content>
                              </content>
                              <content styleCode="underline"> associated diarrhea (CDAD)</content>: Evaluate if diarrhea occurs (<linkHtml href="#LINK_ef165767-6b0c-4b8f-9ea2-d07e2fb68aed">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Based on animal findings, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate (<linkHtml href="#LINK_c11e7010-4473-40e0-bfae-e5743f6ca469">5.7</linkHtml>)</item>
                           <item>Exacerbation of myasthenia gravis has been reported in patients receiving clarithromycin therapy. (<linkHtml href="#LINK_7b716710-06f7-4ecb-8e85-d3646a8a39a6">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_85eabefe-49a6-4e59-9481-e0067c53da5d">
                     <id root="81cb9cb1-cb46-41d5-a52b-63ff55bb0f85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Severe Acute Hypersensitivity
Reactions</title>
                     <text>
                        <paragraph>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, and acute generalized exanthematous pustulosis, discontinue clarithromycin therapy immediately and institute appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_86fe4024-e4f4-4584-a1d8-981636e977d4">
                     <id root="7e434ef0-0ec0-40f1-aca7-7c78f6f6235c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 QT Prolongation</title>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of <content styleCode="italics">torsades de pointes</content> have been spontaneously reported during postmarketing surveillance in patients receiving clarithromycin. Fatalities have been reported.</item>
                        </list>
                        <paragraph>Avoid clarithromycin in the following patients:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including <content styleCode="italics">torsades de pointes</content>
                           </item>
                           <item>patients receiving drugs known to prolong the QT interval <content styleCode="italics">[see also Contraindications (<linkHtml href="#www.splportal.comLINK_e4f59c92-5998-40cc-8578-7e798f91b9a0">4.2</linkHtml>)]</content>
                           </item>
                           <item>patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia and in patients receiving Class IA (e.g., quinidine, procainamide, disopyramide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents.</item>
                        </list>
                        <paragraph>Elderly patients may be more susceptible to drug-associated effects on the QT interval <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">8.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0de9d9c3-5d44-4afd-9664-d1738d5da0f5">
                     <id root="26a4aa6e-6f48-4199-9aea-8c4617793f48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">
                     <id root="9262b6f1-063d-40b3-bb00-1806d1b602f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Serious Adverse Reactions
Due to Concomitant Use with Other Drugs</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drugs metabolized by CYP3A4:</content> Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., <content styleCode="italics">torsades de pointes</content>) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older. Use clarithromycin with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme. The use of clarithromycin with lomitapide, simvastatin, lovastatin, ergotamine, or dihydroergotamine is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>, <linkHtml href="#www.splportal.comLINK_9cc1f8ed-10f1-4f31-9b7e-b75811026030">4.6</linkHtml>) and Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Colchicine:</content> Life-threatening and fatal drug interactions have been reported in patients treated with clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine. Monitor patients for clinical symptoms of colchicine toxicity. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_02bb0cce-26c0-4867-aee8-467b7d6f1b4b">4.4</linkHtml>) and Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Lomitapide:</content> Concomitant use of clarithromycin with lomitapide is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>)]</content>. Lomitapide is metabolized by CYP3A4, and concomitant treatment with clarithromycin increases the plasma concentration of lomitapide, which increases the risk of elevation in transaminases <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>. If treatment with clarithromycin cannot be avoided, therapy with lomitapide must be suspended during the course of treatment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">HMG-CoA Reductase Inhibitors (statins):</content> Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>)]</content> as these statins are extensively metabolized by CYP3A4, and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Cases of rhabdomyolysis have been reported in patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</paragraph>
                        <paragraph>Exercise caution when prescribing clarithromycin with atorvastatin or pravastatin. In situations where the concomitant use of clarithromycin with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should not exceed 40 mg daily. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. It is recommended to prescribe the lowest registered dose if concomitant use cannot be avoided.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Oral Hypoglycemic Agents/Insulin:</content> The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Quetiapine:</content> Use quetiapine and clarithromycin concomitantly with caution. Co-administration could result in increased quetiapine exposure and quetiapine related toxicities such as somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Oral Anticoagulants:</content> There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. Monitor INR and prothrombin times frequently while patients are receiving clarithromycin and oral anticoagulants concurrently <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Benzodiazepines:</content> Increased sedation and prolongation of sedation have been reported with concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam and midazolam <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dcd66ff1-2750-4123-954f-3e51c29a6980">
                     <id root="601af46c-a406-4e09-a4fc-de09c98cb9c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 All-Cause Mortality
in Patients with Coronary Artery Disease 1 to 10 Years After Clarithromycin Exposure</title>
                     <text>
                        <paragraph>In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality one year or more after the end of treatment was observed in patients randomized to receive clarithromycin.<sup>1</sup> Clarithromycin for treatment of coronary artery disease is not an approved indication. The cause of the increased risk has not been established. Other epidemiologic studies evaluating this risk have shown variable results <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_127971eb-b5d1-4852-a542-f1249aeef4f6">6.1</linkHtml>)]</content>. Consider balancing this potential risk with the treatment benefits when prescribing clarithromycin in patients who have suspected or confirmed coronary artery disease.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ef165767-6b0c-4b8f-9ea2-d07e2fb68aed">
                     <id root="de22ed2e-f9f2-478d-8a51-bc70fd220329"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 <content styleCode="italics">Clostridium difficile</content> Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridium difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c11e7010-4473-40e0-bfae-e5743f6ca469">
                     <id root="19f2cba9-0470-437e-93d7-4e0a7f71ad5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If clarithromycin is used during pregnancy, or if pregnancy occurs while the patient is taking this drug, the patient should be apprised of the potential hazard to the fetus. Clarithromycin demonstrated adverse effects on pregnancy outcome and/or embryo-fetal development, including fetal malformations, in pregnant animals administered oral clarithromycin <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7b716710-06f7-4ecb-8e85-d3646a8a39a6">
                     <id root="c1b2a4e1-8cee-47c6-93ec-37518b74edf0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Exacerbation of Myasthenia
Gravis</title>
                     <text>
                        <paragraph>Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving clarithromycin therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b8f47f1b-fc4c-4adf-aeb4-95dba7582b6a">
                     <id root="d5c15159-a9aa-4ace-83f3-0c6cf75388ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Development of Drug Resistant
Bacteria</title>
                     <text>
                        <paragraph>Prescribing clarithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0178f8ac-a85d-403a-aa95-816dd29368aa">
               <id root="70a576a7-435f-498f-a06d-2204d95bf12e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Acute Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_85eabefe-49a6-4e59-9481-e0067c53da5d">5.1</linkHtml>)]</content>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_86fe4024-e4f4-4584-a1d8-981636e977d4">5.2</linkHtml>)]</content>
                        <br/>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_0de9d9c3-5d44-4afd-9664-d1738d5da0f5">5.3</linkHtml>)]</content>
                        <br/>
                     </item>
                     <item>Serious Adverse Reactions Due to Concomitant Use with Other Drugs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>
                        <br/>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridium difficile</content> Associated Diarrhea <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_ef165767-6b0c-4b8f-9ea2-d07e2fb68aed">5.6</linkHtml>)]</content>
                        <br/>
                     </item>
                     <item>Exacerbation of Myasthenia Gravis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7b716710-06f7-4ecb-8e85-d3646a8a39a6">5.8</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most frequent adverse reactions for both adult and pediatric populations in clinical trials: abdominal pain, diarrhea, nausea, vomiting, dysgeusia (<linkHtml href="#LINK_127971eb-b5d1-4852-a542-f1249aeef4f6">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_127971eb-b5d1-4852-a542-f1249aeef4f6">
                     <id root="0b7484bb-d6bd-481c-9caa-a4d260a2fa13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Based on pooled data across all indications, the most frequent adverse reactions for both adult and pediatric populations observed in clinical trials are abdominal pain, diarrhea, nausea, vomiting and dysgeusia. Also reported were dyspepsia, liver function test abnormal, anaphylactic reaction, candidiasis, headache, insomnia, and rash.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Less Frequent Adverse Reactions Observed During Clinical Trials of Clarithromycin </content>
                        </paragraph>
                        <paragraph>Based on pooled data across all indications, the following adverse reactions were observed in clinical trials with clarithromycin at a rate less than 1%: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders: </content>Leukopenia, neutropenia, thrombocythemia, eosinophilia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders: </content>Electrocardiogram QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders: </content>Vertigo, tinnitus, hearing impaired</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders: </content>Stomatitis, glossitis, esophagitis, gastroesophageal reflux disease, gastritis, proctalgia, abdominal distension, constipation, dry mouth, eructation, flatulence</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions: </content>Malaise, pyrexia, asthenia, chest pain, chills, fatigue </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders: </content>Cholestasis, hepatitis </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders: </content>Hypersensitivity </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations: </content>Cellulitis, gastroenteritis, infection, vaginal infection </paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations: </content>Blood bilirubin increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, albumin globulin ratio abnormal </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition Disorders: </content>Anorexia, decreased appetite </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>Myalgia, muscle spasms, nuchal rigidity </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders: </content>Dizziness, tremor, loss of consciousness, dyskinesia, somnolence </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders: </content>Anxiety, nervousness </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders: </content>Blood creatinine increased, blood urea increased </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders: </content>Asthma, epistaxis, pulmonary embolism </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>Urticaria, dermatitis bullous, pruritus, hyperhidrosis, rash maculo-papular</paragraph>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>In the acute exacerbation of chronic bronchitis and acute maxillary sinusitis studies overall gastrointestinal adverse reactions were reported by a similar proportion of patients taking either clarithromycin immediate-release tablets or clarithromycin extended-release tablets; however, patients taking clarithromycin extended-release tablets reported significantly less severe gastrointestinal symptoms compared to patients taking clarithromycin immediate-release tablets. In addition, patients taking clarithromycin extended-release tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse reactions compared to clarithromycin immediate-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="underline">All-Cause Mortality in Patients with Coronary Artery Disease 1 to 10 Years Following Clarithromycin Exposure</content>
                        </paragraph>
                        <paragraph>In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality was observed in patients randomized to clarithromycin. Clarithromycin for treatment of coronary artery disease is not an approved indication. Patients were treated with clarithromycin or placebo for 14 days and observed for primary outcome events (e.g., all-cause mortality or non-fatal cardiac events) for several years.<sup>1</sup> A numerically higher number of primary outcome events in patients randomized to receive clarithromycin was observed with a hazard ratio of 1.06 (95% confidence interval 0.98 to 1.14). However, at follow-up 10 years post-treatment, there were 866 (40%) deaths in the clarithromycin group and 815 (37%) deaths in the placebo group that represented a hazard ratio for all-cause mortality of 1.10 (95% confidence interval 1.00 to 1.21). The difference in the number of deaths emerged after one year or more after the end of treatment.</paragraph>
                        <paragraph> The cause of the difference in all-cause mortality has not been established. Other epidemiologic studies evaluating this risk have shown variable results <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_dcd66ff1-2750-4123-954f-3e51c29a6980">5.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b20edcb6-9f68-4353-8898-5d80825692de">
                     <id root="77627e09-19a1-4545-9aec-1e5304d4ad7a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of clarithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System:</content> Thrombocytopenia, agranulocytosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac:</content> Ventricular arrhythmia, ventricular tachycardia, <content styleCode="italics">torsades de pointes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth:</content> Deafness was reported chiefly in elderly women and was usually reversible.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> Pancreatitis acute, tongue discoloration, tooth discoloration was reported and was usually reversible with professional cleaning upon discontinuation of the drug.</paragraph>
                        <paragraph>There have been reports of clarithromycin extended-release tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibacterial drug.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary:</content> Hepatic failure, jaundice hepatocellular. Adverse reactions related to hepatic dysfunction have been reported with clarithromycin <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_86fe4024-e4f4-4584-a1d8-981636e977d4">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations:</content> Pseudomembranous colitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_ef165767-6b0c-4b8f-9ea2-d07e2fb68aed">5.6</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System:</content> Anaphylactic reactions, angioedema</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> Prothrombin time prolonged, white blood cell count decreased, international normalized ratio increased. Abnormal urine color has been reported, associated with hepatic failure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition:</content> Hypoglycemia has been reported in patients taking oral hypoglycemic agents or insulin.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue:</content> Myopathy rhabdomyolysis was reported and in some of the reports, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>) and Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> Parosmia, anosmia, ageusia, paresthesia and convulsions</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content> Abnormal behavior, confusional state, depersonalization, disorientation, hallucination, depression, manic behavior, abnormal dream, psychotic disorder. These disorders usually resolve upon discontinuation of the drug.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary:</content> Nephritis interstitial, renal failure</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue:</content> Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne, acute generalized exanthematous pustulosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular:</content> Hemorrhage<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">
               <id root="bc3b8389-aea0-4938-9670-08c80e005317"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.</paragraph>
                  <paragraph> Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.</paragraph>
                  <table width="1000px" cellspacing="0" cellpadding="5" border="1">
                     <caption>Table 8: Clinically Significant Drug Interactions with Clarithromycin</caption>
                     <col width="1pt"/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="3">
                              <paragraph>
                                 <content styleCode="bold">Drugs That Are Affected By </content>
                                 <content styleCode="bold">Clarithromycin</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Drug(s) with<br/>
                                 </content>
                                 <content styleCode="bold">P</content>
                                 <content styleCode="bold">h</content>
                                 <content styleCode="bold">armacokinetics </content>
                                 <content styleCode="bold">Affected<br/>
            by </content>
                                 <content styleCode="bold">Clarithromycin</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="bold">Recommendation</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="bold">Comments</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Antiarrhythmics:</paragraph>
                              <paragraph>Disopyramide<br/>
            Quinidine<br/>
            Dofetilide<br/>
            Amiodarone<br/>
            Sotalol<br/>
            Procainamide</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>Not<br/>
            Recommended</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Disopyramide, Quinidine:</content> There have been postmarketing reports of <content styleCode="italics">torsades de pointes </content>occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during co-administration of clarithromycin with these drugs<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_86fe4024-e4f4-4584-a1d8-981636e977d4">5.2</linkHtml>)]</content>.</paragraph>
                              <paragraph>Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine.</paragraph>
                              <paragraph>There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Digoxin</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Digoxin:</content> Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Oral Anticoagulants:</paragraph>
                              <paragraph>Warfarin</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Oral anticoagulants:</content> Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Antiepileptics: </paragraph>
                              <paragraph>Carbamazepine</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">C</content>
                                 <content styleCode="underline">ar</content>
                                 <content styleCode="underline">bamazepine:</content> Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Antifungals: </paragraph>
                              <paragraph>Itraconazole</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">I</content>
                                 <content styleCode="underline">traconazole:</content> Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin” in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Fluconazole</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>No Dose</paragraph>
                              <paragraph>Adjustment</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">F</content>
                                 <content styleCode="underline">luconazole: </content>
                                 <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Anti-Gout Agents:</paragraph>
                              <paragraph>Colchicine (in patients with renal or hepatic impairment)</paragraph>
                              <paragraph>Colchicine (in patients with normal renal and hepatic function)</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Contraindicated</paragraph>
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">C</content>
                                 <content styleCode="underline">olchicine:</content> Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_02bb0cce-26c0-4867-aee8-467b7d6f1b4b">4.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Antipsychotics: </paragraph>
                              <paragraph>Pimozide </paragraph>
                              <paragraph>Quetiapine</paragraph>
                              <paragraph>Lurasidone</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Contraindicated</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">P</content>
                                 <content styleCode="underline">imozide: </content>
                                 <content styleCode="italics">[See Contraindications (<linkHtml href="#www.splportal.comLINK_e4f59c92-5998-40cc-8578-7e798f91b9a0">4.2</linkHtml>)]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Quetiapine:</content> Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Co-administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Lurasidone</content>: <content styleCode="italics">[See Contraindications (<linkHtml href="#LINK_85c174c5-5b08-4ad3-8048-7377df78b3d7">4.7</linkHtml>)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Antispasmodics:</paragraph>
                              <paragraph>Tolterodine (patients deficient in CYP2D6 activity)</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Tolterodine:</content> The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Antivirals:</paragraph>
                              <paragraph>Atazanavir</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Atazanavir:</content> Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin” in the table below) <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Saquinavir (in patients with decreased renal function)</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule"/>
                           <td>
                              <paragraph>
                                 <content styleCode="underline">S</content>
                                 <content styleCode="underline">a</content>
                                 <content styleCode="underline">quinavir:</content> Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin” in the table below) <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Ritonavir</paragraph>
                              <paragraph>Etravirine</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule"/>
                           <td>
                              <paragraph>
                                 <content styleCode="underline">R</content>
                                 <content styleCode="underline">itonavir, Etravirine:</content> (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin” in the table below) <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Maraviroc</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule"/>
                           <td>
                              <paragraph>
                                 <content styleCode="underline">Maraviroc:</content> Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry<sup>®</sup> prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule">
                              <paragraph>Boceprevir (in patients with normal renal function)</paragraph>
                              <paragraph>Didanosine</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>No Dose</paragraph>
                              <paragraph>Adjustment</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">B</content>
                                 <content styleCode="underline">oceprevir:</content> Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis<sup>®</sup> prescribing information).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Zidovudine</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule"/>
                           <td>
                              <paragraph>
                                 <content styleCode="underline">Z</content>
                                 <content styleCode="underline">idovudine:</content> Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>The impact of co-administration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Calcium Channel<br/>
            Blockers:</paragraph>
                              <paragraph>Verapamil</paragraph>
                              <paragraph>Amlodipine<br/>
            Diltiazem</paragraph>
                              <paragraph>Nifedipine</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Verapamil:</content> Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Amlodipine, Diltiazem:</content>
                                 <content styleCode="italics">[See Warnings and </content>
                                 <content styleCode="italics">Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Nifedipine:</content> Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Ergot Alkaloids:</paragraph>
                              <paragraph>Ergotamine<br/>
            Dihydroergotamine</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Contraindicated</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Ergotamine, Dihydroergotamine:</content> Postmarketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_9cc1f8ed-10f1-4f31-9b7e-b75811026030">4.6</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Gastroprokinetic<br/>
            Agents:</paragraph>
                              <paragraph>Cisapride</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Contraindicated</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">C</content>
                                 <content styleCode="underline">isapride:</content> <content styleCode="italics">[See Contraindications (<linkHtml href="#www.splportal.comLINK_e4f59c92-5998-40cc-8578-7e798f91b9a0">4.2</linkHtml>)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Lipid-lowering agents:</paragraph>
                              <paragraph>Lomitapide<br/>
            Lovastatin<br/>
            Simvastatin</paragraph>
                              <paragraph>Atorvastatin<br/>
            Pravastatin<br/>
            Fluvastatin</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Contraindicated</paragraph>
                              <paragraph>
            Use With Caution</paragraph>
                              <paragraph>No Dose<br/>
            Adjustment</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Lomitapide, L</content>
                                 <content styleCode="underline">ovastatin, Simvastatin:<br/>
                                 </content>Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_f599c9bd-a9ac-4b6d-8dc2-2f71e31a6527">4.5</linkHtml>) and Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">
                                    <br/>
                                    <br/>
            Atorvastatin, Pravastatin, </content>
                                 <content styleCode="underline">Fluvastatin:<br/>
                                 </content>
                                 <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Hypoglycemic Agents:</paragraph>
                              <paragraph>Nateglinide Pioglitazone Repaglinide Rosiglitazone</paragraph>
                              <paragraph>Insulin</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Nateglinide, Pioglitazone, Repaglinide, </content>
                                 <content styleCode="underline">Rosiglitazone: </content>
                                 <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>) and Adverse Reactions (<linkHtml href="#www.splportal.comLINK_b20edcb6-9f68-4353-8898-5d80825692de">6.2</linkHtml>)]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">I</content>
                                 <content styleCode="underline">nsulin: </content>
                                 <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>) and </content>
                                 <content styleCode="italics">Adverse Reactions (<linkHtml href="#www.splportal.comLINK_b20edcb6-9f68-4353-8898-5d80825692de">6.2</linkHtml>)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Immunosuppressants: </paragraph>
                              <paragraph>Cyclosporine</paragraph>
                              <paragraph>Tacrolimus</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">C</content>
                                 <content styleCode="underline">y</content>
                                 <content styleCode="underline">c</content>
                                 <content styleCode="underline">losporine:</content> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Tacrolimus:</content> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Phosphodiesterase inhibitors:</paragraph>
                              <paragraph>Sildenafil<br/>
            Tadalafil<br/>
            Vardenafil</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">S</content>
                                 <content styleCode="underline">ildenafil, Tadalafil, Vardenafil:</content> Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Proton Pump Inhibitors: </paragraph>
                              <paragraph>Omeprazole</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>No Dose<br/>
            Adjustment</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Omeprazole:</content> The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin as a result of increased omeprazole exposures <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)] </content>(see also Omeprazole under “Drugs That Affect Clarithromycin” in the table below).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Xanthine Derivatives: </paragraph>
                              <paragraph>Theophylline</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Theophylline:</content> Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Triazolobenzodiazepines and Other Related Benzodiazepines:</paragraph>
                              <paragraph>Midazolam</paragraph>
                              <paragraph>Alprazolam<br/>
            Triazolam</paragraph>
                              <paragraph>Temazepam<br/>
            Nitrazepam<br/>
            Lorazepam</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                              <paragraph>No Dose<br/>
            Adjustment</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Midazolam:</content> When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>) and Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Triazolam, Alprazolam:</content> Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</paragraph>
                              <paragraph>In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Temazepam, Nitrazepam, Lorazepam:</content> For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Cytochrome P450<br/>
            Inducers:</paragraph>
                              <paragraph>Rifabutin</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">R</content>
                                 <content styleCode="underline">ifabutin:</content> Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin” in the table below).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Other Drugs<br/>
            Metabolized by CYP3A:</paragraph>
                              <paragraph>Alfentanil<br/>
            Bromocriptine<br/>
            Cilostazol<br/>
            Methylprednisole<br/>
            Vinblastine<br/>
            Phenobarbital<br/>
            St. John’s Wort</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A:</paragraph>
                              <paragraph>Hexobarbital<br/>
            Phenytoin<br/>
            Valproate</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Drugs that Affect </content>
                                 <content styleCode="bold">C</content>
                                 <content styleCode="bold">larithromycin</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Drug(s) that Affect the Pharmacokinetics of </content>
                                 <content styleCode="bold">C</content>
                                 <content styleCode="bold">larithromycin</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="bold">Recommendation</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="bold">Comments</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Antifungals: </paragraph>
                              <paragraph>Itraconazole</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">I</content>
                                 <content styleCode="underline">traconazole:</content> Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin” in the table above).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Antivirals: </paragraph>
                              <paragraph>Atazanavir</paragraph>
                              <paragraph>Ritonavir (in patients with decreased renal function)</paragraph>
                              <paragraph>Saquinavir (in patients with decreased renal function)</paragraph>
                              <paragraph>Etravirine</paragraph>
                              <paragraph>Saquinavir (in patients with normal renal function)</paragraph>
                              <paragraph>Ritonavir (in patients with normal renal function)</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                              <paragraph>No Dose<br/>
            Adjustment</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Atazanavir:</content> When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50% <content styleCode="italics">[see Clinical Pharmacology </content>
                                 <content styleCode="italics">(</content>
                                 <content styleCode="italics">
                                    <linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to <content styleCode="italics">Mycobacterium avium </content>complex. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">R</content>
                                 <content styleCode="underline">itonavir:</content> Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to <content styleCode="italics">Mycobacterium avium [see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">S</content>
                                 <content styleCode="underline">a</content>
                                 <content styleCode="underline">quinavir:</content> When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above) <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Etravirine:</content> Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against <content styleCode="italics">Mycobacterium avium </content>complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Proton Pump Inhibitors: </paragraph>
                              <paragraph>Omeprazole</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>
                                 <content styleCode="underline">Omeprazole:</content> Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole <content styleCode="italics">[see Pharmacokinetics (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>Miscellaneous<br/>
            Cytochrome P450<br/>
            Inducers:</paragraph>
                              <paragraph>Efavirenz<br/>
            Nevirapine<br/>
            Rifampicin<br/>
            Rifabutin<br/>
            Rifapentine</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Use With Caution</paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin” in the table above).</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Co-administration of clarithromycin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy. (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>, <linkHtml href="#LINK_86fe4024-e4f4-4584-a1d8-981636e977d4">5.2</linkHtml>, <linkHtml href="#LINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>, <linkHtml href="#LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_28761c98-8bbc-4b25-802b-2f81d5f044d1">
               <id root="086dede8-5ed7-45db-a6f0-e586c8100b21"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Geriatric: Increased risk of <content styleCode="italics">torsades de pointes</content> (<linkHtml href="#LINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">8.5</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9db656bc-75ac-43c9-a8ea-adf611a00791">
                     <id root="1e588735-5afd-4c3e-8b6d-0bb8203431c4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking clarithromycin, the patient should be apprised of the potential hazard to the fetus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_c11e7010-4473-40e0-bfae-e5743f6ca469">5.7</linkHtml>)]</content>.</paragraph>
                        <paragraph>Limited data from a small number of published human studies with clarithromycin use during pregnancy are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of oral clarithromycin to pregnant mice, rats, rabbits, and monkeys during the period of organogenesis produced malformations in rats (cardiovascular anomalies) and mice (cleft palate) at clinically relevant doses based on body surface area comparison. Fetal effects in mice, rats, and monkeys (e.g., reduced fetal survival, body weight, body weight gain) and implantation losses in rabbits were generally considered to be secondary to maternal toxicity (see Data).</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Animal reproduction studies were conducted in mice, rats, rabbits, and monkeys with oral and intravenously administered clarithromycin. In pregnant mice, clarithromycin was administered during organogenesis (gestation day [GD] 6 to 15) at oral doses of 15, 60, 250, 500, or 1000 mg/kg/day. Reduced body weight observed in dams at 1000 mg/kg/day (3 times the maximum recommended human dose [MRHD] based on body surface area comparison) resulted in reduced survival and body weight of the fetuses. At ≥ 500 mg/kg/day, increases in the incidence of post-implantation loss and cleft palate in the fetuses were observed. No adverse developmental effects were observed in mice at ≤ 250 mg/kg/day (≤ 1 times MRHD based on body surface area</paragraph>
                        <paragraph>comparison).</paragraph>
                        <paragraph>In pregnant Sprague Dawley rats, clarithromycin was administered during organogenesis (GD 6 to 15) at oral doses of 15, 50, or 150 mg/kg/day. Reductions in body weight and food consumption were observed in dams at 150 mg/kg/day. Increased resorptions and reduced body weight of the fetuses at this dose were considered secondary to maternal toxicity. Additionally, at 150 mg/kg/day (1 times MRHD based on body surface area comparison), a low incidence of cardiovascular anomalies (complete situs inversus, undivided truncus, IV septal defect) was observed in the fetuses. Clarithromycin did not cause adverse developmental effects in rats at 50 mg/kg/day (0.3 times MRHD based on body surface area comparison). Intravenous dosing of clarithromycin during organogenesis in rats (GD 6 to 15) at 15, 50, or 160 mg/kg/day was associated with maternal toxicity (reduced body weight, body-weight gain, and food consumption) at 160 mg/kg/day but no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).</paragraph>
                        <paragraph>In pregnant Wistar rats, clarithromycin was administered during organogenesis (GD 7 to 17) at oral doses of 10, 40, or 160 mg/kg/day. Reduced body weight and food consumption were observed in dams at 160 mg/kg/day but there was no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).</paragraph>
                        <paragraph>In pregnant rabbits, clarithromycin administered during organogenesis (GD 6 to 18) at oral doses of 10, 35, or 125 mg/kg/day resulted in reduced maternal food consumption and decreased body weight at the highest dose, with no evidence of any adverse developmental effects at any dose (≤ 2 times MRHD based on body surface area comparison). Intravenously administered clarithromycin to pregnant rabbits during organogenesis (GD 6 to 18) in rabbits at 20, 40, 80, or 160 mg/kg/day (≥ 0.3 times MRHD based on body surface area comparison) resulted in maternal toxicity and implantation losses at all doses.</paragraph>
                        <paragraph>In pregnant monkeys, clarithromycin was administered (GD 20 to 50) at oral doses of 35 or 70 mg/kg/day. Dose-dependent emesis, poor appetite, fecal changes, and reduced body weight were observed in dams at all doses (≥ 0.5 times MRHD based on body surface area comparison). Growth retardation in 1 fetus at 70 mg/kg/day was considered secondary to maternal toxicity. There was no evidence of primary drug related adverse developmental effects at any dose tested.</paragraph>
                        <paragraph>In a reproductive toxicology study in rats administered oral clarithromycin late in gestation through lactation (GD 17 to post-natal day 21) at doses of 10, 40, or 160 mg/kg/day (≤ 1 times MRHD based on body surface area comparison), reductions in maternal body weight and food consumption were observed at 160 mg/kg/day. Reduced body-weight gain observed in offspring at 160 mg/kg/day was considered secondary to maternal toxicity. No adverse developmental effects were observed with clarithromycin at any dose tested. </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ccdfd3f6-fe62-46ae-924d-ce86089d36b5">
                     <id root="07a3d7a9-b28c-4614-a1b5-25f7d45c4d1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on limited human data, clarithromycin and its active metabolite 14-OH clarithromycin are present in human milk at less than 2% of the maternal weight-adjusted dose (see Data). In a separate observational study, reported adverse effects on breast-fed children (rash, diarrhea, loss of appetite, somnolence) were comparable to amoxicillin (see Data). No data are available to assess the effects of clarithromycin or 14-OH clarithromycin on milk production.</paragraph>
                        <paragraph>The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for clarithromycin and any potential adverse effects on the breast-fed child from clarithromycin or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human</content>
                        </paragraph>
                        <paragraph>Serum and milk samples were obtained after 3 days of treatment, at steady state, from one published study of 12 lactating women who were taking clarithromycin 250 mg orally twice daily. Based on the limited data from this study, and assuming milk consumption of 150 mL/kg/day, an exclusively human milk fed infant would receive an estimated average of 136 mcg/kg/day of clarithromycin and its active metabolite, with this maternal dosage regimen. This is less than 2% of the maternal weight-adjusted dose (7.8 mg/kg/day, based on the average maternal weight of 64 kg), and less than 1% of the pediatric dose (15 mg/kg/day) for children greater than 6 months of age.</paragraph>
                        <paragraph>A prospective observational study of 55 breastfed infants of mothers taking a macrolide antibacterial (6 were exposed to clarithromycin) were compared to 36 breastfed infants of mothers taking amoxicillin. Adverse reactions were comparable in both groups. Adverse reactions occurred in 12.7% of infants exposed to macrolides and included rash, diarrhea, loss of appetite, and somnolence. </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c8d68c91-d39c-4861-a99b-63f774483a8d">
                     <id root="946427a4-71db-46e3-b03a-20ad435939a0"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Females and Males of Reproductive
Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Administration of clarithromycin resulted in testicular atrophy in rats, dogs and monkeys <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_7dfb4b13-fed6-4f25-bc49-5068301c5035">13.1</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_171b24a7-4705-4986-92cb-c6072bd3b89f">
                     <id root="7da961ca-c031-40e6-9989-f1265fc0e616"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of clarithromycin extended-release tablets in the treatment of pediatric patients has not been established.</paragraph>
                        <paragraph> Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established. The safety of clarithromycin has not been studied in MAC patients under the age of 20 months.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">
                     <id root="792327df-b1ca-4505-86c7-01478bdf09a3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In a steady-state study in which healthy elderly subjects (65 years to 81 years of age) were given 500 mg of clarithromycin every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function. In clinical trials, elderly patients did not have an increased incidence of adverse reactions when compared to younger patients. Consider dosage adjustment in elderly patients with severe renal impairment. Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_0de9d9c3-5d44-4afd-9664-d1738d5da0f5">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine) involved elderly patients 65 years of age or older <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Especially in elderly patients, there have been reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, some of which occurred in patients with renal insufficiency. Deaths have been reported in some patients <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_02bb0cce-26c0-4867-aee8-467b7d6f1b4b">4.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6d12ceb2-e93a-4d6f-ad45-84e359c9bd6e">5.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7928ee5a-4a35-4285-b6c0-3c1fe164eded">
                     <id root="60e2cfcc-2400-4c7f-b69a-dadd4e1c5fc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal and Hepatic
Impairment</title>
                     <text>
                        <paragraph>Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_8d65fe9b-433d-4f67-abce-86e17dc87e62">2.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f6fd962b-f628-433f-86eb-f3aa2e3ed599">
               <id root="aeb226bd-77c5-4810-8c63-9947a918a552"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage of clarithromycin can cause gastrointestinal symptoms such as abdominal pain, vomiting, nausea, and diarrhea.</paragraph>
                  <paragraph> Treat adverse reactions accompanying overdosage by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="LINK_83adff9a-52a3-419f-8aed-73ac0c008fd4">
               <id root="751434bd-33eb-48c6-b95b-1bea6a5887b0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Clarithromycin, USP is a semi-synthetic macrolide antimicrobial for oral use. Chemically, it is 6-0­ methylerythromycin. The molecular formula is C<sub>38</sub>H<sub>69</sub>NO<sub>13</sub>, and the molecular weight is 747.95. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Structure of Clarithromycin</content>
                  </paragraph>
                  <paragraph>Clarithromycin, USP is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water.</paragraph>
                  <paragraph>Each yellow oval film-coated unscored clarithromycin extended-release tablet, for oral administration, contains 500 mg of clarithromycin and the following inactive ingredients: compressible sugar, D&amp;C yellow #10 Aluminum Lake, glycerol monostearate, polyethylene glycol 3000, polyvinyl alcohol, sodium phosphate monobasic (anhydrous), talc and titanium dioxide.</paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b47070b3-fd47-42ba-a89c-8eb73f10beba">
               <id root="5401f17a-87b4-4216-b00b-a0806023db54"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="LINK_123199df-feb1-4f49-9546-3affcc838e51">
                     <id root="c8e3bfc5-7e00-4267-b8df-a839556290d9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Clarithromycin is a macrolide antimicrobial drug <content styleCode="italics">[see Microbiology (<linkHtml href="#www.splportal.comLINK_6fa8670a-8900-43c4-b3b9-1239836c8fa9">12.4</linkHtml>)].</content>
                           <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">
                     <id root="68f9f3d4-ef43-471d-8875-c0499cd615ab"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clarithromycin </content>
                           <content styleCode="italics">Extended-Release Tablets</content>
                        </paragraph>
                        <paragraph>Clarithromycin extended-release tablets provide extended absorption of clarithromycin from the gastrointestinal tract after oral administration. Relative to an equal total daily dose of immediate- release clarithromycin tablets, clarithromycin extended-release tablets provide lower and later steady-state peak plasma concentrations but equivalent 24-hour AUCs for both clarithromycin and its microbiologically-active metabolite, 14-OH clarithromycin. While the extent of formation of 14-OH clarithromycin following administration of clarithromycin extended-release tablets (2 x 500 mg tablets once daily) is not affected by food, administration under fasting conditions is associated with approximately 30% lower clarithromycin AUC relative to administration with food. Therefore, clarithromycin extended-release tablets should be taken with food.</paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph>
                           <content styleCode="bold">Figure 2: Steady-State Clarithromycin Plasma Concentration-Time Profiles</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids. There are no data available on cerebrospinal fluid penetration. Because of high intracellular concentrations, tissue concentrations are higher than serum concentrations. Examples of tissue and serum concentrations are presented below.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="0" border="1">
                           <caption>Table 9. Tissue and Serum Concentrations of Clarithromycin</caption>
                           <col width="423.75pt"/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" colspan="3">
                                    <paragraph>
                                       <content styleCode="bold">CONCENTRATION (after 250 mg every 12 hours)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule">
                                    <paragraph>
                                       <content styleCode="bold">T</content>
                                       <content styleCode="bold">issue Type</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">T</content>
                                       <content styleCode="bold">issue</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(</content>
                                       <content styleCode="bold">m</content>
                                       <content styleCode="bold">c</content>
                                       <content styleCode="bold">g/g)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">S</content>
                                       <content styleCode="bold">er</content>
                                       <content styleCode="bold">u</content>
                                       <content styleCode="bold">m</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(</content>
                                       <content styleCode="bold">m</content>
                                       <content styleCode="bold">c</content>
                                       <content styleCode="bold">g/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule">
                                    <paragraph>Tonsil</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>0.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule">
                                    <paragraph>Lung</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>8.8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>1.7</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clarithromycin </content>
                           <content styleCode="italics">Extended-Release Tablets</content>
                        </paragraph>
                        <paragraph>In healthy human subjects, steady-state peak plasma clarithromycin concentrations of approximately 2 mcg/mL to 3 mcg/mL were achieved about 5 hours to 8 hours after oral administration of 1000 mg clarithromycin extended-release tablets once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.8 mcg/mL were attained about 6 hours to 9 hours after dosing. Steady-state peak plasma clarithromycin concentrations of approximately 1 mcg/mL to 2 mcg/mL were achieved about 5 hours to 6 hours after oral administration of a single 500 mg clarithromycin extended-release tablet once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.6 mcg/mL were attained about 6 hours after dosing.</paragraph>
                        <paragraph>Steady-state peak plasma concentrations were attained in 2 days to 3 days and were approximately 2 mcg/mL for clarithromycin and 0.7 mcg/mL for 14-OH clarithromycin when 250-mg doses of the clarithromycin suspension were administered every 12 hours. Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations for Clarithromycin Extended-Release Tablets</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">HIV Infection</content>
                        </paragraph>
                        <paragraph>Steady-state concentrations of clarithromycin and 14-OH clarithromycin observed following administration of 500 mg doses of clarithromycin every 12 hours to adult patients with HIV infection were similar to those observed in healthy volunteers. In adult HIV-infected patients taking 500-mg or 1000-mg doses of clarithromycin every 12 hours, steady-state clarithromycin C<sub>max</sub> values ranged from 2 mcg/mL to 4 mcg/mL and 5 mcg/mL to 10 mcg/mL, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The steady-state concentrations of clarithromycin in subjects with impaired hepatic function did not differ from those in normal subjects; however, the 14-OH clarithromycin concentrations were lower in the hepatically impaired subjects. The decreased formation of 14-OH clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the subjects with impaired hepatic function when compared to healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of clarithromycin was also altered in subjects with impaired renal function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_7928ee5a-4a35-4285-b6c0-3c1fe164eded">8.6</linkHtml>) and Dosage and Administration (<linkHtml href="#www.splportal.comLINK_8d65fe9b-433d-4f67-abce-86e17dc87e62">2.6</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fluconazole</content>
                        </paragraph>
                        <paragraph>Following administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state clarithromycin C<sub>min</sub> and AUC increased 33% and 18%, respectively. Clarithromycin exposures were increased and steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Colchicine</content>
                        </paragraph>
                        <paragraph>When a single dose of colchicine 0.6 mg was administered with clarithromycin 250 mg BID for 7 days, the colchicine C<sub>max</sub> increased 197% and the AUC<sub>0-∞ </sub>increased 239% compared to administration of colchicine alone.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Atazanavir</content>
                        </paragraph>
                        <paragraph>Following administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the clarithromycin AUC increased 94%, the 14-OH clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ritonavir</content>
                        </paragraph>
                        <paragraph>Concomitant administration of clarithromycin and ritonavir (n = 22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Saquinavir</content>
                        </paragraph>
                        <paragraph>Following administration of clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and C<sub>max</sub> increased 177% and 187% respectively compared to administration of saquinavir alone. Clarithromycin AUC and C<sub>max</sub> increased 45% and 39% respectively, whereas the 14–OH clarithromycin AUC and C<sub>max</sub> decreased 24% and 34% respectively, compared to administration with clarithromycin alone.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Didanosine</content>
                        </paragraph>
                        <paragraph>Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Zidovudine</content>
                        </paragraph>
                        <paragraph>Following administration of clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. When clarithromycin tablets were administered two to four hours prior to zidovudine, the steady- state zidovudine C<sub>max</sub> increased 100% whereas the AUC was unaffected (n=24).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Omeprazole</content>
                        </paragraph>
                        <paragraph>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (C<sub>max</sub>, AUC<sub>0-24</sub>, and t1/2 increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin.</paragraph>
                        <paragraph>The plasma levels of clarithromycin and 14–OH clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean C<sub>max</sub> was 10% greater, the mean C<sub>min</sub> was 27% greater, and the mean AUC<sub>0-8 </sub>was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14–OH clarithromycin, the mean C<sub>max</sub> was 45% greater, the mean C<sub>min</sub> was 57% greater, and the mean AUC<sub>0-8 </sub>was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="0" border="1">
                           <caption>Clarithromycin Tissue Concentrations 2 hours after Dose (mcg/mL)/(mcg/g)</caption>
                           <col width="1px"/>
                           <col width="medium"/>
                           <col width="medium"/>
                           <col width="medium"/>
                           <col width="medium"/>
                           <col width="medium"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Toprule">
                                    <paragraph>
                                       <content styleCode="bold">T</content>
                                       <content styleCode="bold">re</content>
                                       <content styleCode="bold">atment</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">antrum</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">f</content>
                                       <content styleCode="bold">u</content>
                                       <content styleCode="bold">n</content>
                                       <content styleCode="bold">dus</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">M</content>
                                       <content styleCode="bold">u</content>
                                       <content styleCode="bold">c</content>
                                       <content styleCode="bold">u</content>
                                       <content styleCode="bold">s</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule">
                                    <paragraph>Clarithromycin</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>10.48 ± 2.01</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>20.81 ± 7.64</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>4.15 ± 7.74</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule">
                                    <paragraph>Clarithromycin + Omeprazole</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>19.96 ± 4.71</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>24.25 ± 6.37</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule">
                                    <paragraph>39.29 ± 32.79</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Theophylline</content>
                        </paragraph>
                        <paragraph>In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of C<sub>max</sub>, C<sub>min</sub>, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Midazolam</content>
                        </paragraph>
                        <paragraph>When a single dose of midazolam was co-administered with clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration.</paragraph>
                        <paragraph>For information about other drugs indicated in combination with clarithromycin, refer to their full prescribing information, CLINICAL PHARMACOLOGY section.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                     <component>
                        <observationMedia ID="MM3">
                           <text>3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6fa8670a-8900-43c4-b3b9-1239836c8fa9">
                     <id root="78b93bd6-7cc5-4fe4-8ae2-ce4fabfcf9fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunit of susceptible bacteria resulting in inhibition of protein synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                           <br/>
                        </paragraph>
                        <paragraph>The major routes of resistance are modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity or drug efflux pumps. Beta-lactamase production should have no effect on clarithromycin activity.</paragraph>
                        <paragraph>Most isolates of methicillin-resistant and oxacillin-resistant staphylococci are resistant to clarithromycin.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Antimicrobial Activity</content>
                           </content>
                           <br/>
                        </paragraph>
                        <paragraph>Clarithromycin has been shown to be active against most of the isolates of the following microorganisms both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see Indications and Usage (<linkHtml href="#www.splportal.comLINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Gram-Positive Bacteria<br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Staphylococcus aureus</content>
                           </item>
                           <item>
                              <content styleCode="italics">Streptococcus pneumoniae</content>
                           </item>
                           <item>
                              <content styleCode="italics">Streptococcus pyogenes</content>
                           </item>
                        </list>
                        <paragraph>Gram-Negative Bacteria<br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Haemophilus influenzae</content>
                           </item>
                           <item>
                              <content styleCode="italics">Haemophilus parainfluenzae</content>
                           </item>
                           <item>
                              <content styleCode="italics">Moraxella catarrhalis</content>
                           </item>
                        </list>
                        <paragraph>Other Microorganisms<br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Chlamydophila pneumoniae</content>
                           </item>
                           <item>
                              <content styleCode="italics">Helicobacter pylori</content>
                           </item>
                           <item>
                              <content styleCode="italics">Mycobacterium avium</content> complex (MAC) consisting of <content styleCode="italics">M. avium</content> and <content styleCode="italics">M. intracellulare</content>
                           </item>
                           <item>
                              <content styleCode="italics">Mycoplasma pneumoniae</content>
                           </item>
                        </list>
                        <paragraph>At least 90 percent of the microorganisms listed below exhibit <content styleCode="italics">in vitro</content> minimum inhibitory concentrations (MICs) less than or equal to the clarithromycin susceptible MIC breakpoint for organisms of similar type to those shown in Table 11. However, the efficacy of clarithromycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.<br/>
                        </paragraph>
                        <paragraph>Gram-Positive Bacteria<br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Streptococcus agalactiae</content>
                           </item>
                           <item>Streptococci (Groups C, F, G)</item>
                           <item>Viridans group streptococci<br/>
                           </item>
                        </list>
                        <paragraph>Gram-Negative Bacteria</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Legionella pneumophila</content>
                           </item>
                           <item>
                              <content styleCode="italics">Pasteurella multocida</content>
                           </item>
                        </list>
                        <paragraph>Anaerobic Bacteria<br/>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Clostridium perfringens</content>
                           </item>
                           <item>
                              <content styleCode="italics">Peptococcus niger</content>
                           </item>
                           <item>
                              <content styleCode="italics">Prevotella melaninogenica</content>
                           </item>
                           <item>
                              <content styleCode="italics">Propionibacterium acnes</content>
                              <br/>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing<br/>
                           </content>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_24ca90b2-6335-4021-b922-370a464aff0f">
               <id root="fbb2cf21-7631-4f9c-b78e-13f953ffe338"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250410"/>
               <component>
                  <section ID="LINK_7dfb4b13-fed6-4f25-bc49-5068301c5035">
                     <id root="6ff3823c-34ec-4505-8ba0-adafd2e4d2b0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> mutagenicity tests have been conducted with clarithromycin:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Salmonella</content>/Mammalian Microsomes Test</item>
                           <item>Bacterial Induced Mutation Frequency Test</item>
                           <item>
                              <content styleCode="italics">In Vitro </content>Chromosome Aberration Test</item>
                           <item>Rat Hepatocyte DNA Synthesis Assay</item>
                           <item>Mouse Lymphoma Assay</item>
                           <item>Mouse Dominant Lethal Study</item>
                           <item>Mouse Micronucleus Test</item>
                        </list>
                        <paragraph>All tests had negative results except the <content styleCode="italics">in vitro</content> chromosome aberration test which was positive in one test and negative in another. In addition, a bacterial reverse-mutation test (Ames test) has been performed on clarithromycin metabolites with negative results.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring. Plasma levels in rats after 150 mg/kg/day were twice the human serum levels.</paragraph>
                        <paragraph> Testicular atrophy occurred in rats at doses 7 times, in dogs at doses 3 times, and in monkeys at doses 8 times greater than the maximum human daily dose (on a body surface area basis).<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_36ead976-2c36-48c0-abad-69dcee4d5ec0">
                     <id root="460a76d8-cb39-4f8f-91b2-16cc1cb04124"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Corneal opacity occurred in dogs at doses 12 times and in monkeys at doses 8 times greater than the maximum human daily dose (on a body surface area basis). Lymphoid depletion occurred in dogs at doses 3 times greater than and in monkeys at doses 2 times greater than the maximum human daily dose (on a body surface area basis).</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5c936aad-7f11-42de-980e-7cdb35367b54">
               <id root="733504a7-0b74-42e8-aed1-a4dfee6486fb"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjøller E, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol 2015;182:459-65.</paragraph>
                  <paragraph>2. Kemper CA, et al. Treatment of Mycobacterium avium Complex Bacteremia in AIDS with a Four-Drug Oral Regimen. <content styleCode="italics">Ann Intern Med.</content> 1992;116:466-472.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="LINK_387b587b-343a-4327-b60a-f786616c708b">
               <id root="2698a79b-151c-49e9-ae37-9dde1120b6e1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Clarithromycin Extended-release Tablets USP are supplied as yellow, film coated, oval shaped, unscored tablets debossed with <renderMultiMedia referencedObject="MM4"/> and “777” on one side.</paragraph>
                  <paragraph>Bottles of 60 (NDC 0591-2805-60).</paragraph>
                  <paragraph> Store Clarithromycin Extended-release Tablets USP at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].<br/>
                  </paragraph>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_fcf3a7bf-ecc7-4005-8ed7-c038b8ade9ef">
               <id root="c2b527dc-055e-413c-8e6e-e53f0c4a4973"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Provide the following instructions or information about clarithromycin extended-release tablets to patients:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients that clarithromycin extended-release tablets should be taken with food. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients that clarithromycin extended-release tablets may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other medications.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials including clarithromycin extended-release tablets which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, instruct patients to contact their healthcare provider as soon as possible.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise females of reproductive potential that that if pregnancy occurs while taking this drug, there is a potential hazard to the fetus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_c11e7010-4473-40e0-bfae-e5743f6ca469">5.7</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Counsel patients that antibacterial drugs including clarithromycin extended-release tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When clarithromycin extended-release tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by clarithromycin extended-release tablets or other antibacterial drugs in the future.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Potential for Dizziness, Vertigo and Confusion</content>
                  </paragraph>
                  <paragraph>There are no data on the effect of clarithromycin extended-release tablets on the ability to drive or use machines. However, counsel patients regarding the potential for dizziness, vertigo, confusion and disorientation, which may occur with the clarithromycin extended-release tablets. The potential for these adverse reactions should be taken into account before patients drive or use machines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risk of Mortality in Patients with Coronary Disease Years After Clarithromycin Extended-release Tablets Treatment</content>
                  </paragraph>
                  <paragraph>Advise patients who have coronary artery disease to continue medications and lifestyle modifications for their coronary artery disease because clarithromycin extended-release tablets may be associated with increased risk for mortality years after the end of clarithromycin extended-release tablets treatment.</paragraph>
                  <paragraph>Brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>Manufactured by:<br/>
Actavis Laboratories FL, Inc.<br/>
Fort Lauderdale, FL 33314 USA</paragraph>
                  <paragraph>Distributed by:<br/>
Actavis Pharma, Inc.<br/>
Parsippany, NJ  07054 USA</paragraph>
                  <paragraph> Rev. F 4/2025                      </paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="LINK_25bc5f47-cfac-4618-9ac8-6caff1aea194">
               <id root="73c2e70b-25d5-4c7d-9d2e-1532889b7af6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0591-2805-60<br/>Clarithromycin Extended-Release Tablets, USP<br/>500 mg<br/>60 Tablets<br/>Rx Only<br/>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>